AstraZeneca PLC (LON:AZN) Receives £152.50 Average Price Target from Analysts

AstraZeneca PLC (LON:AZN) has been given an average recommendation of “Moderate Buy” by the six research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is £152.50.

AZN has been the subject of several recent research reports. Berenberg Bank lifted their target price on shares of AstraZeneca from £145 to £160 and gave the company a “buy” rating in a report on Tuesday, January 27th. Jefferies Financial Group reaffirmed a “buy” rating and set a £180 target price on shares of AstraZeneca in a report on Friday, April 10th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Citigroup lifted their target price on shares of AstraZeneca from £170 to £180 and gave the company a “buy” rating in a report on Friday, April 10th. Finally, Shore Capital Group reaffirmed a “buy” rating on shares of AstraZeneca in a report on Friday, January 16th.

AstraZeneca Stock Performance

Shares of LON AZN opened at £148.04 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.59 and a debt-to-equity ratio of 60.87. AstraZeneca has a 12 month low of GBX 9,651 and a 12 month high of £157.32. The company has a 50 day simple moving average of £147.75 and a two-hundred day simple moving average of £138.38. The stock has a market cap of £229.59 billion, a price-to-earnings ratio of 22.64, a PEG ratio of 0.86 and a beta of 0.28.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.